Vascular Targeted Photodynamic Therapy for Prostate Tumors

VIDEO | 01:53

Urologic surgeon Jonathan Coleman discusses vascular targeted photodynamic (VTP) therapy to destroy prostate tumors and the blood vessels that support them by delivering the intravenous drug TOOKAD®. The drug is activated inside tissues by exposing it to light of a very specific wavelength, delivered to the tumor site via specially designed fibers placed within the prostate. The procedure achieves excellent outcomes in terms of cancer cure, and may even be a potential therapy for prostate cancers that have spread to the lymph nodes and other organs. VTP is being evaluated in a clinical trial at Memorial Sloan Kettering Cancer Center.